Skip to search boxSkip to navigationSkip to main content

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

  • Stéphane de Botton
    ,
  • Pierre Fenaux
    ,
  • Karen Yee
    ,
  • Christian Récher
    ,
  • Andrew H. Wei
    ,
  • Pau Montesinos
*Corresponding author for this work
  • Institut Gustave Roussy
    ,
  • Université Paris Cité
    ,
  • Princess Margaret Hospital
    ,
  • CHU de Toulouse
    ,
  • Monash University
    ,
  • Hospital Universitario La Fe
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor–naive patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib monotherapy 150 mg twice daily in the pivotal cohort of this study. The median age of participants was 71 years (range, 32-87 years) and the median number of prior regimens received by patients was 2 (1-7). The rate of complete remission (CR) plus CR with partial hematologic recovery (CRh) was 35%, and the overall response rate was 48%. Response rates were similar in patients who had, and who had not, received prior venetoclax. With 55% of patients censored at the time of data cut-off, the median duration of CR/CRh was 25.9 months. The median duration of overall response was 11.7 months, and the median overall survival was 11.6 months. Of 86 patients who were transfusion dependent at baseline, a 56-day transfusion independence was achieved in 29 (34%), which included patients in all response groups. Grade 3 or 4 treatment-emergent adverse events (≥10%) were febrile neutropenia and anemia (n = 31; 20% each), thrombocytopenia (n = 25; 16%), and neutropenia (n = 20; 13%). Differentiation syndrome adverse events of special interest occurred in 22 (14%) patients, with 14 (9%) grade ≥3 and 1 fatal case reported. Overall, olutasidenib induced durable remissions and transfusion independence with a well-characterized and manageable side effect profile. The observed efficacy represents a therapeutic advance in this molecularly defined, poor-prognostic population of patients with mIDH1 R/R AML.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3117-3127 (11 pages)

Journal (Volume, Issue Number)

Blood Advances (Volume 7, Issue 13)

Publication milestones

  • Published - 07/11/2023

Publication status

Published - 07/11/2023

ISSN

2473-9529

Publication IDs

  • Scopus: 85149709096
  • PubMed: 36724515
  • ORCID: /0000-0002-8636-1071/work/157548429

Publication metrics

Metrics

Fractional count
1
Fractional count
0.03
Fractional count
28
Fractional count
0.97
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
128
Captures
61
Mentions
1166

Funding Details

Medical writing support was provided by Patrick Barry (Acumen Medical Communications) and was funded by Forma Therapeutics, Inc. This study was funded by Forma Therapeutics, Inc. D.C.T. is supported by the National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre.
FundersFunding numbers
Forma Therapeutics, Inc.
-
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
-
National Institute for Health Research Royal Marsden
-